ConductScience.org, home

Paper36992136

Impact of MERS-CoV and SARS-CoV-2 Viral Infection on Immunoglobulin-IgG Cross-Reactivity.

AlKhalifah JM and 7 others. Vaccines (Basel), 2023. Cited by 15 papers, by iCite.

Cite this record

ConductScience Library. Impact of MERS-CoV and SARS-CoV-2 Viral Infection on Immunoglobulin-IgG Cross-Reactivity. Papers, record 36992136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36992136

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Impact of MERS-CoV and SARS-CoV-2 Viral Infection on Immunoglobulin-IgG Cross-Reactivity.
PubMed
Journal
Vaccines (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
1.05
iCite
Revised in PubMed
2023-04-01
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1AlKhalifah JMJoud Mohammedhttps://orcid.org/0000-0003-3474-625X
2Seddiq WWaleedhttps://orcid.org/0000-0002-2756-029X
3Alshehri MAMohammed Abdullah
4Alhetheel AAbdulkarim
5Albarrag AAhmed
6Meo SASultan Ayoubhttps://orcid.org/0000-0001-9820-1852
7Al-Tawfiq JAJaffar Ahttps://orcid.org/0000-0002-5752-2235
8Barry MMazinhttps://orcid.org/0000-0003-2274-007X

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
RSP 2023 R 47King Saud University, Riyadh, Saudi ArabiaPubMed

Source PubMed

Download CSV of grants

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133159009Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.Science2020https://conductscience.org/library/papers/33159009PubMed
231978945A Novel Coronavirus from Patients with Pneumonia in China, 2019.N Engl J Med2020https://conductscience.org/library/papers/31978945PubMed
336539527The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.Nat Rev Immunol2023https://conductscience.org/library/papers/36539527PubMed
432344314Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents.Med Hypotheses2020https://conductscience.org/library/papers/32344314PubMed
519239338Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease.J Infect Dis2009https://conductscience.org/library/papers/19239338PubMed
627287409Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses.Immunity2016https://conductscience.org/library/papers/27287409PubMed
733320447Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.Immun Inflamm Dis2021https://conductscience.org/library/papers/33320447PubMed
836713397The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants.Front Immunol2022https://conductscience.org/library/papers/36713397PubMed
922673931Differences in neutralizing antigenicity between laboratory and clinical isolates of HCoV-229E isolated in Japan in 2004-2008 depend on the S1 region sequence of the spike protein.J Gen Virol2012https://conductscience.org/library/papers/22673931PubMed
1023782161Hospital outbreak of Middle East respiratory syndrome coronavirus.N Engl J Med2013https://conductscience.org/library/papers/23782161PubMed
1132758887Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities.Med Hypotheses2020https://conductscience.org/library/papers/32758887PubMed
1234603300Potential Cross-Reactive Immunity to COVID-19 Infection in Individuals With Laboratory-Confirmed MERS-CoV Infection: A National Retrospective Cohort Study From Saudi Arabia.Front Immunol2021https://conductscience.org/library/papers/34603300PubMed
1319342289Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus.J Clin Virol2009https://conductscience.org/library/papers/19342289PubMed
1432898238Sustained Responses of Neutralizing Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Recovered Patients and Their Therapeutic Applicability.Clin Infect Dis2021https://conductscience.org/library/papers/32898238PubMed
1529263263Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.J Virol2018https://conductscience.org/library/papers/29263263PubMed
1616479513Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome.J Infect Dis2006https://conductscience.org/library/papers/16479513PubMed
1723075143Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.N Engl J Med2012https://conductscience.org/library/papers/23075143PubMed
1834260272
Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and First Steps towards Global Harmonization of COVID-19 Antibody Methods.
J Clin Microbiol2021https://conductscience.org/library/papers/34260272PubMed
1929864486Healthcare-associated infections: the hallmark of Middle East respiratory syndrome coronavirus with review of the literature.J Hosp Infect2019https://conductscience.org/library/papers/29864486PubMed
2032073157Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses.J Med Virol2020https://conductscience.org/library/papers/32073157PubMed

See all 37 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
42328241Original Antigenic Sin on Antibody Response in SARS-CoV-2 Infection.Infect Dis Immun2024https://conductscience.org/library/papers/42328241PubMed
41274935Colostrum from MERS-CoV seropositive camels for MERS prophylaxis and SARS-CoV-2 infection, a placebo controlled randomized trial.Sci Rep2025https://conductscience.org/library/papers/41274935PubMed
40774254Highly conserved Betacoronavirus sequences are broadly recognized by human T cells.Cell2025https://conductscience.org/library/papers/40774254PubMed
40455375Recurrent MERS-CoV Transmission in Saudi Arabia- Renewed Lessons in Healthcare Preparedness and Surveillance.J Epidemiol Glob Health2025https://conductscience.org/library/papers/40455375PubMed
40359129Comprehensive analysis of human coronavirus antibody responses in ICU and non-ICU COVID-19 patients reveals IgG3 against SARS-CoV-2 spike protein as a key biomarker of disease severity.J Med Microbiol2025https://conductscience.org/library/papers/40359129PubMed
39822038A 10 Year Long-Lived Cellular and Humoral MERS-CoV Immunity Cross-Recognizing the Wild-Type and Variants of SARS-CoV-2: A Potential One-Way MERS-CoV Cross-Protection Toward a Pan-Coronavirus Vaccine.J Med Virol2025https://conductscience.org/library/papers/39822038PubMed
39288758Gestational SARS-CoV-2 Infection in a Ugandan Birth Cohort: High Incidence, Mild Maternal Disease, and Evidence of Association with Transient Infant Stunting.Am J Trop Med Hyg2024https://conductscience.org/library/papers/39288758PubMed
39125749Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein.Int J Mol Sci2024https://conductscience.org/library/papers/39125749PubMed
38543668Back to the Future: Immune Protection or Enhancement of Future Coronaviruses.Microorganisms2024https://conductscience.org/library/papers/38543668PubMed
38448564Neutralizing immunity against coronaviruses in Tanzanian health care workers.Sci Rep2024https://conductscience.org/library/papers/38448564PubMed
38416834Rise in broadly cross-reactive adaptive immunity against human β-coronaviruses in MERS-recovered patients during the COVID-19 pandemic.Sci Adv2024https://conductscience.org/library/papers/38416834PubMed
37777266The role of cross-reactive immunity to emerging coronaviruses: Implications for novel universal mucosal vaccine design.Saudi Med J2023https://conductscience.org/library/papers/37777266PubMed
37242383Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies.Pathogens2023https://conductscience.org/library/papers/37242383PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36992136

GET https://conductscience.org/api/papers/v1/36992136/references?page=2